Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Editas Medicine Inc (DE:8EM)
FRANKFURT:8EM
Holding DE:8EM?
Track your performance easily
See the Price Targets and Ratings of:
8EM Analyst Ratings
Moderate Buy
6 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
8EM Stock 12 Month Forecast
Average Price Target
€9.87
▲(229.38% Upside)
| Highest Price Target€16.16 | Average Price Target€9.87 | Lowest Price Target€6.28 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
Assigned
09/19/24
JonesTrading
Initiated
09/17/24
Truist Financial
Reiterated
08/08/24
Morgan Stanley
Reiterated
08/08/24
Evercore ISI
Assigned
08/08/24
Barclays
Reiterated
08/08/24
Bank of America Securities
Upgraded
08/08/24
TD Cowen
Reiterated
08/07/24
Citi
Reiterated
08/07/24
Robert W. Baird
Reiterated
08/07/24
Leerink Partners
€7.18
Hold
139.55%
Upside
Assigned
08/07/24
Editas Medicine Hold Rating with Revised Price Target Amidst Mixed Financial Signals
Oppenheimer
€10.77
Hold
259.32%
Upside
Reiterated
06/18/24
Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), GeoVax Labs (NASDAQ: GOVX) and Editas Medicine (NASDAQ: EDIT)
J.P. Morgan
€7.18→€8.08
Hold
169.49%
Upside
Reiterated
02/27/24
Editas Medicine (EDIT) PT Raised to $9 at JPMorganJPMorgan analyst Brian Cheng raised the price target on Editas Medicine (NASDAQ: EDIT) to $9.00 (from $8.00) while maintaining a Neutral rating.
Chardan Capital
€17.95
Buy
498.87%
Upside
Reiterated
12/13/23
Buy Rating Affirmed for Editas Medicine Amid Strategic Partnerships and Promising Treatment Data
Best Analysts Covering Editas Medicine
Which Analyst Should I Follow If I Want to Buy DE:8EM and Sell After:
1 Month
xxx
Success Rate
12/34 ratings generated profit
Average Return
+2.77%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.29% of your transactions generating a profit, with an average return of +2.77% per trade.
3 Months
xxx
Success Rate
13/34 ratings generated profit
Average Return
-1.48%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.24% of your transactions generating a profit, with an average return of -1.48% per trade.
1 Year
Success Rate
14/34 ratings generated profit
Average Return
-6.24%
reiterated a buy rating 10 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -6.24% per trade.
2 Years
xxx
Success Rate
7/13 ratings generated profit
Average Return
+30.72%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +30.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
8EM Analyst Recommendation Trends
Rating
Mar 24
May 24
Jun 24
Aug 24
Sep 24
Strong Buy
4
5
4
8
6
Buy
3
3
2
2
2
Hold
7
13
11
16
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
21
17
26
18
Each month's total comprises the sum of three months' worth of ratings.
8EM Financial Forecast
8EM Stock Forecast FAQ
What is DE:8EM’s average 12-month price target, according to analysts?
Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is €9.87.
What is DE:8EM’s upside potential, based on the analysts’ average price target?
Editas Medicine Inc has 229.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Editas Medicine Inc a Buy, Sell or Hold?
Editas Medicine Inc has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 5 hold ratings and 0 sell ratings.
What is Editas Medicine Inc’s share price target?
The average share price target for Editas Medicine Inc is €9.87. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.16 ,and the lowest forecast is €6.28. The average share price target represents 229.38% Increase from the current price of €2.998.
The highest analyst share price target is €16.16 ,and the lowest forecast is €6.28. The average share price target represents 229.38% Increase from the current price of €2.998.
What do analysts say about Editas Medicine Inc?
Editas Medicine Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of Editas Medicine Inc?
To buy shares of DE:8EM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.